20 of 22 patients with suspected allergic reactions were women; 17 met Brighton anaphylaxis criteria
Most Highly Allergic People Can Be Safely Immunized Against COVID-19
Algorithm enables immunization of most individuals, with 0.7 percent developing anaphylactic reaction after one BNT162b2 dose
Most With Reaction to mRNA COVID-19 Vaccine Tolerate Second Dose
Most patients with immediate, potentially allergic reaction to Pfizer-BioNTech or Moderna mRNA COVID-19 vaccine tolerate second dose
Guidance Updated for Assessing Allergy Risk of COVID-19 Vaccines
Janssen adenovirus type 26 vectored vaccine may be considered for individuals who self-report PEG allergy
NIH Starts Trial Looking at Rare Allergic Reactions to COVID-19 Vaccines
Research will also address biological mechanism causing the reactions and whether there is a way to predict risk
ACAAI Updates Guidance for Allergic Reactions to COVID-19 Vaccines
Guidance relates to risks for allergic reactions for mRNA (Moderna and Pfizer) and adenovirus vector (Johnson & Johnson) COVID-19 vaccines
Rates of Acute Allergic Reactions to COVID-19 Vaccines Extremely Low
Most recipients with anaphylaxis had allergy histories, with 31 percent having prior anaphylaxis
2.5 Anaphylaxis Cases Reported Per Million COVID-19 Moderna Vaccine Shots
Nine of the 10 cases occurred in individuals with documented history of allergies, allergic reactions
Allergists Affirm Safety of COVID-19 Vaccines for Most
All patients should be observed for 15 minutes after vaccination; staff should be trained in anaphylaxis management
11.1 Anaphylaxis Cases/Million Doses of Pfizer-BioNTech COVID-19 Vaccine Reported
Median interval from vaccine receipt to symptom onset was 13 minutes
- Page 1 of 2
- 1
- 2